Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights ...

2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...
Pharmabiz

Roche’s phase III ALLEGORY study of Gazyva/Gazyvaro in adults with systemic lupus erythematosus meets its primary endpoint

Roche’s phase III ALLEGORY study of Gazyva/Gazyvaro in adults with systemic lupus erythematosus meets its primary endpoint: Basel Tuesday, November 4, 2025, 12:00 Hrs [IST] Roch ...

Vertex signals 8–9% 2025 revenue growth as renal pipeline accelerates and ALYFTREK, JOURNAVX launches drive diversification

Get insights from Vertex Pharmaceuticals' Q3 2025 earnings call—revenue growth, pipeline milestones, and outlook for ALYFTREK, CASGEVY, and JOURNAVX.
eLife

Glucose-stimulated KIF5B-driven microtubule sliding organizes microtubule networks in mouse pancreatic β cells

Sub-membrane microtubule array, known to prevent excessive glucose-stimulated insulin secretion, depends on kinesin-1 KIF5B, which moves microtubules to both generate and remodel this array, ...

Vertex Reports Third Quarter 2025 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.